工程NKG2CNK-like T细胞表现出优越的抗瘤疗效,同时减轻了细胞因子释放综合征
bioRxiv : the preprint server for biology
|August 30, 2024
概括
工程NKG2C+NK样T细胞提供了更安全,更持久的癌症治疗方法. 与当前的CAR-T和CAR-NK治疗相比,这些细胞显示出优异的瘤清除和减少的副作用.
科学领域:
- 免疫治疗是一种免疫疗法.
- 细胞疗法细胞疗法
- 在瘤学瘤学.
背景情况:
- 工程T和NK细胞疗法对血液恶性瘤和固体瘤有希望.
- 目前的仿真抗原受体 (CAR) T细胞疗法与细胞因子释放综合征 (CRS) 和免疫衰竭有关.
- 卡尔-NK疗法缺乏足够的体内持续性.
研究的目的:
- 评估NKG2C+NK样T细胞作为工程细胞疗法的平台.
- 为了比较CAR工程NKG2C+NK样T细胞与传统CAR-T和CAR-NK细胞的疗效和安全性.
- 评估TCR工程NKG2C+NK样T细胞对瘤的控制和消耗.
主要方法:
- 鉴定和NKG2C+NK样T细胞的体外扩张.
- 用第二代CD19 CAR (1928z) 转导NKG2C+NK样T细胞.
- 工程NKG2C+NK样T细胞与一个针对NY-ESO-1抗原的TCR.
- 在瘤模型中,工程NKG2C+NK样T细胞与传统CAR-T和CAR-NK细胞进行比较.
主要成果:
- 与传统的CAR-T细胞相比,CAR修饰的NKG2C+NK样T细胞表现出优异的瘤清除和更长的持续时间.
- 与CAR-T细胞相比,CAR-NKG2C+NK样T细胞的CRS显著减少.
- 工程NKG2C+NK样T细胞显示出强大的瘤控制与最小的疲劳,超过TCR工程传统CD8T细胞.
- 卡尔-NK细胞在体内持久性有限.
结论:
- NKG2C+ NK型T细胞代表了细胞工程的强大平台.
- 工程NKG2C+NK样T细胞为当前的CAR-T和CAR-NK疗法提供了更安全,更持久的替代方案.
- 这种方法有可能改善癌症治疗结果.
相关概念视频
Cytotoxic T Cells-mediated Immune Response
861
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
861
Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
154


